1 Abbreviated Title: GBM Pembro HSPPC Version Date: 03/26/2024 Abbreviated Title: GBM Pembro HSPPC NIH Protocol #: 17C0034 Version Date: 03/26/2024 NCT Number: NCT03018288 Title: A randomized, double blind phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM) Coordinating Center: BTTC Coordinating Center, Center for Cancer Research, NCI Responsible DSMB: NCI Data Safety Monitoring Board NCI Principal Investigator: Byram H. Ozer, M.D., Ph.D. Neuro Oncology Branch (NOB), CCR, NCI 9030 Old Georgetown Road, Building 82, Room 217 Bethesda, MD 20892 Phone: 240-760-6316 Email: byram.ozer@nih.gov Drug Name: HSPPC-96 Pembrolizumab Temozolomide IND Number:17203 17203 17203 Sponsor: National Cancer Institute, Center for Cancer ResearchNational Cancer Institute, Center for Cancer ResearchNational Cancer Institute, Center for Cancer Research Manufacturer: Agenus Merck generic Supplier: Agenus Merck CC Pharmacy 2 Abbreviated Title: GBM Pembro HSPPC Version Date: 03/26/2024 LEAD PI AND STUDY CHAIR Byram H. Ozer, M.D., Ph.D.